scholarly journals Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open‐label feasibility trial

2021 ◽  
Author(s):  
M. Goebeler ◽  
Z. Bata‐Csörgő ◽  
C. De Simone ◽  
B. Didona ◽  
E. Remenyik ◽  
...  
Keyword(s):  
Pemphigus Vulgaris ◽  
Fc Receptor ◽  
Feasibility Trial ◽  
Phase 2 ◽  
Neonatal Fc Receptor ◽  
Open Label ◽  
Receptor Inhibitor

scholarly journals 035 Humanized anti-Desmoglein-3 antibodies as tools for research on the role of the neonatal Fc receptor in pemphigus vulgaris

2021 ◽  
Vol 141 (10) ◽  
pp. S154
Author(s):  
A. Zakrzewicz ◽  
C. Würth ◽  
B. Beckert ◽  
S. Feldhoff ◽  
P. Verheesen ◽  
...  
Keyword(s):  
Pemphigus Vulgaris ◽  
Fc Receptor ◽  
Neonatal Fc Receptor ◽  
Desmoglein 3

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

2017 ◽  
Vol 1 ◽  
pp. s12
Author(s):  
Andrew Blauvelt ◽  
Craig Leonardi ◽  
Claus Zachariae ◽  
Russel Burge ◽  
Terri Ridenour ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Phase 2 ◽  
Chronic Plaque Psoriasis ◽  
Open Label ◽  
Phase 2 Study ◽  
Health Related

Abstract Not Available

Sign in / Sign up

Export Citation Format

Share Document